Meropenem is commonly prescribed in critically ill children for targeted therapy in severe and multidrug-resistant bacterial infections. Meropenem, as a carbapenem, has a time-dependent bactericidal effect. Optimal dosing is evaluated based on the ability to maintain meropenem concentrations in plasma above the minimum inhibitory concentration (MIC) of the infecting pathogen throughout the dosing interval (fT > MIC) (1, 2). However, the optimal clinical pharmacokinetic/pharmacodynamic (PK/PD) target remains uncertain as it varies from 50% fT > MIC to 100% fT > 4× MIC. The latter would be desirable for critically ill patients (3, 4)

中文翻译：

---

接受CKRT的儿科患者如何使用美罗培南？危重儿童美罗培南综合药代动力学模型

美罗培南通常用于危重儿童的严重和多重耐药细菌感染的靶向治疗。美罗培南作为碳青霉烯类，具有时间依赖性杀菌作用。最佳剂量的评估基于在整个给药间隔内将血浆中美罗培南浓度维持在感染病原体的最低抑制浓度 (MIC) 以上的能力 (fT > MIC) (1, 2)。然而，最佳临床药代动力学/药效学 (PK/PD) 目标仍不确定，因为它从 50% fT > MIC 到 100% fT > 4× MIC 不等。后者对于重症患者来说是理想的选择 (3, 4)